User menu

Improved Glycemic Control with metformin Glibenclamide combined tablet therapy (Glucovance® ) in type 2 diabetic patients inadequately controlled on metformin

Bibliographic reference Marre, M. ; Allavoine, Th. ; Lehert, Philippe ; Howlett, H.. Improved Glycemic Control with metformin Glibenclamide combined tablet therapy (Glucovance® ) in type 2 diabetic patients inadequately controlled on metformin. In: Diabetic Medicine, Vol. 19, p. 673-680 (2002)
Permanent URL http://hdl.handle.net/2078/20207
  1. UK Prospective Diabetes Study Group., Lancet, 352, 837 (1998)
  2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), 10.1016/s0140-6736(98)07037-8
  3. Stratton I. M, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, 10.1136/bmj.321.7258.405
  4. American Diabetes Association., Diabetes Care, 22, S1 (1999)
  5. European Diabetes Policy Group 1999, A desktop guide to Type 2 diabetes mellitus, 10.1046/j.1464-5491.1999.00166.x
  6. Campbell I. W., Howlett H. C. S., Worldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis, 10.1002/dmr.5610110509
  7. Bailey CJ, Br J Cardiol, 7, 350 (2000)
  8. Campbell IW, Br J Cardiol, 7, 625 (2000)
  9. Turner Robert C., Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49), 10.1001/jama.281.21.2005
  10. New J. P., Hollis S., Campbell F., McDowell D., Burns E., Dornan T. L., Young R. J., Measuring clinical performance and outcomes from diabetes information systems: an observational study, 10.1007/s001250051458
  11. DeFronzo Ralph A., Pharmacologic Therapy for Type 2 Diabetes Mellitus, 10.7326/0003-4819-131-4-199908170-00008
  12. Wiernsperger NF, Drugs, 58, 31 (1999)
  13. Bailey Clifford J, Insulin resistance and antidiabetic drugs, 10.1016/s0006-2952(99)00191-4
  14. Bailey Clifford J., Turner Robert C., Metformin, 10.1056/nejm199602293340906
  15. Campbell IW, Drugs, 60, 1017 (2000)
  16. Hermann L. S., Biguanides and Sulfonylureas as Combination Therapy in NIDDM, 10.2337/diacare.13.3.37
  17. Hermann LS, Diabetes Care, 17, 1100 (1994)
  18. Hermann LS, Diabet Med, 11, 953 (1994)
  19. Frison L, Stat Med, 11, 1685 (1992)
  20. Box GEP, J Roy Statist Soc (Series B), 26, 211 (1964)
  21. 21H Scheffe . The Analysis of Variance. New York: Wiley, 1959 : 477 .
  22. Marena S, Diabetes Metab, 20, 15 (1994)
  23. Garber AJ, Diabetes, 49, 432 (2000)
  24. UK Prospective Diabetes Study (UKPDS) Group., Diabetes Care, 21, 87 (1998)
  25. DeFronzo Ralph A., Goodman Anita M., Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus, 10.1056/nejm199508313330902
  26. Charpentier G., Fleury F., Kabir M., Vaur L., Halimi S., Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients, 10.1046/j.1464-5491.2001.00582.x
  27. Moses R, Diabetes Care, 22, 119 (1999)
  28. Howlett HC, Drug Saf, 20, 489 (1999)
  29. Haffner Steven M., Lehto Seppo, Rönnemaa Tapani, Pyörälä Kalevi, Laakso Markku, Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction, 10.1056/nejm199807233390404
  30. Reaven G., Role of Insulin Resistance in Human Disease (syndrome X): An Expanded Definition, 10.1146/annurev.med.44.1.121
  31. Reaven GM, Blood Press, 4, 13 (1992)
  32. Turner R C, Millns H, Neil H A W, Stratton I M, Manley S E, Matthews D R, Holman R R, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23), 10.1136/bmj.316.7134.823
  33. Krentz AJ, Drug Saf, 11, 223 (1994)
  34. Bailey Clifford J, Grant Peter J, The UK Prospective Diabetes study, 10.1016/s0140-6736(98)00090-7
  35. Veehof L., Stewart R., Haaijer-Ruskamp F., Jong B M.-d., The development of polypharmacy. A longitudinal study, 10.1093/fampra/17.3.261
  36. Paes AHP, Diabetes Care, 20, 1512 (1997)
  37. BROWN J, NICHOLS G, GLAUBER H, BAKST A, Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus, 10.1016/s0149-2918(99)80023-x
  38. Morris AD, Diabetes, 49, A76 (2000)